Heterogeneous nuclear ribonucleoprotein B1 expression in malignant mesothelioma

Cancer Science

Volumn 97, Issue 11, 2006, Pages 1175-1181

  Hiraki, Akio ^a,b   Murakami, Tomoyuki ^a   Aoe, Keisuke ^a   Sueoka, Eisaburo ^c   Sueoka, Naoko ^c   Taguchi, Koji ^d   Kamei, Toshiaki ^e   Sugi, Kazuro ^a   Ueoka, Hiroshi ^a   Kishimoto, Takumi ^d  

^a NATIONAL SANYO HOSPITAL   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c SAGA UNIVERSITY   (Japan)

^d OKAYAMA ROSAI HOSPITAL   (Japan)

^e Yamaguchi Grand Medical Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1; MESSENGER RNA; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG RESECTION; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; PRECANCER; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; CELL PROLIFERATION; EPITHELIUM; FEMALE; FLOW CYTOMETRY; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURA; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 33748919488     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00311.x     Document Type: Article

References (24)

1. Treasure T, Sedrakyan A. Pleural mesothelioma: Little evidence, still time to do trials. Lancet 2004; 364: 1183-5.
2. Zellos LS, Sugarbaker DJ. Diffuse malignant mesothelioma of the pleural space and its management. Oncology 2002; 16: 907-13.
3. Mohamed F, Sugarbaker PH. Peritoneal mesothelioma. Curr Treat Options Oncol 2002; 3: 375-86.
4. Burgers JA, Damhuis RA. Prognostic factors in malignant mesothelioma. Lung Cancer 2004; 45(Suppl. 1): 49-54.
5. Edwards JG, Abrams KR, Leverment JN et al. Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems. Thorax 2000; 55: 731-5.
6. Bass P, Schouwink H, Zoetmulder FAN. Malignant pleural mesothelioma. Annal Oncol 1998; 9: 139-49.
7. Bongiovanni M, Cassoni P, De Giuli P et al. p27 (kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer 2001; 92: 1245-50.
8. Baldi A, Santini D, Vasaturo F et al. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax 2004; 59: 428-33.
9. Tockman MS, Gupta PK, Myers JD et al. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: A new approach to early lung cancer detection. J Clin Oncol 1988; 6: 1685-93.
10. Kozu T, Henrich B, Schafer KP. Structure and expression of the gene (HNRPA2B1) encoding the human hnRNP protein A2/B1. Genomics 1995; 25: 365-71.
11. Sueoka E, Sueoka N, Goto Y et al. Heterogeneous nuclear ribonucleoprotein B1 as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia. Cancer Res 2001; 61: 1896-902.
12. Matsuyama S, Goto Y, Sueoka N et al. Heterogeneous nuclear ribonucleoprotein B1 expressed in esophageal squamous cell carcinomas as a new biomarker for diagnosis. Jpn J Cancer Res 2000; 91: 658-63.
13. Goto Y, Sueoka E, Chiba H et al. Significance of heterogeneous nuclear ribonucleoprotein B1 as a new early detection marker for oral squamous cell carcinoma. Jpn J Cancer Res 1999; 90: 1358-63.
14. Satoh H, Ishikawa H, Kamma H et al. HnRNP A2/B1 proteins in nontumorous alveolar cells. Lung 2003; 181: 219-25.
15. Tani H, Ohshima K, Haraoka S et al. Overexpression of heterogeneous nuclear ribonucleoprotein B1 in lymphoproliferative disorders: High expression in cells of follicular center origin. Int J Oncol 2002; 21: 957-63.
16. Montuenga LM, Zhou J, Avis I et al. Expression of heterogeneous nuclear ribonucleoprotein A2/B1 changes with critical stages of mammalian lung development. Am J Respir Cell Mol Biol 1998; 19: 554-62.
17. Churg A, Roggli V, Galateau-Salle F et al. Mesothelioma. In: Travis WD, Brambilla E, Müller-Hermelink HK et al., eds. World Health Organization Classification of Tumours. Pathology and Genetics. Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004; 128-36.
18. Gerdes J, Schwab U, Lemke H et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
19. Gerdes J. Determination of the growth fraction by means of immunostaining with monoclonal antibody Ki-67. Acta Histochem Suppl 1988; 36: 437-46.
20. Sasaki K, Murakami T, Kawasaki M et al. The cell cycle-associated change of Ki-67 reactive nuclear antigen expression. J Cell Physiol 1987; 133: 579-84.
21. Leonardo E, Zanconati F, Bonifacio D et al. Immunohistochemical MIB-1 and p27 (kip1) as prognostic factors in pleural mesothelioma. Pathol Res Pract 2001; 197: 253-6.
22. Haga Y, Hiroshima K, Iyoda A et al. Ki-67 expression and prognosis for smokers with resected stage I non-small cell lung cancer. Ann Thorac Surg 2003; 75: 1727-33.
23. Allegra CJ, Paik S, Colangelo LH et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes'B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003; 21: 241-50.
24. Tani H, Ohshima K, Haraoka S et al. Reduced expression of heterogeneous nuclear ribonucleoprotein B1 in adult T-cell lymphoma/leukemia. Int J Oncol 2003; 22: 529-34.